Circulating immune checkpoints predict heart failure outcomes

Circulating immune checkpoints predict heart failure outcomes

Abstract Aims There are limited data examining the role of immune checkpoint (IC) ligands in the pathophysiology of heart failure (HF). Therefore, we explore this in three HF animal models and in three different human cohorts (healthy, stable, and worsening HF). Methods and results Transcriptomic an...

Bibliografski detalji
Glavni autori:	Elles M. Screever, Laura I.E. Yousif, Javid J. Moslehi, Joe‐Elie Salem, Adriaan A. Voors, Herman H.W. Silljé, Rudolf A. deBoer, Wouter C. Meijers
Format:	Članak
Jezik:	English
Izdano:	Wiley 2023-08-01
Serija:	ESC Heart Failure
Teme:	Immune checkpoints PD‐L1 PD‐L2 Galectin‐9 Heart failure
Online pristup:	https://doi.org/10.1002/ehf2.14304

Slični predmeti

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
od: Douglas B. Johnson, i dr.
Izdano: (2019-05-01)

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
od: Federica Costa, i dr.
Izdano: (2018-09-01)

The role of immune checkpoints in cardiovascular disease
od: Laura I. Yousif, i dr.
Izdano: (2022-10-01)

Enhancing cancer care with improved checkpoint inhibitors
od: Vickram A S, i dr.
Izdano: (2024-10-01)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
od: Ruby Dhar, i dr.
Izdano: (2023-04-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
od: Kazuhiko Hashimoto, i dr.
Izdano: (2020-07-01)

Immune Checkpoint in Glioblastoma: Promising and Challenging
od: Jing Huang, i dr.
Izdano: (2017-05-01)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
od: Juwon Lee, i dr.
Izdano: (2021-07-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
od: Ruiting Li, i dr.
Izdano: (2021-06-01)

On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy
od: Sai Mummareddy, i dr.
Izdano: (2021-12-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
od: Tianrui Yang, i dr.
Izdano: (2021-02-01)

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
od: Jan Willem Kleinovink, i dr.
Izdano: (2017-04-01)

Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
od: Sebastian Marwitz, i dr.
Izdano: (2017-05-01)

Immune Checkpoint Inhibitors in Cancer Therapy
od: Yavar Shiravand, i dr.
Izdano: (2022-04-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
od: YU Lin, i dr.
Izdano: (2021-08-01)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
od: Ahmed M. Basudan
Izdano: (2022-12-01)

The role of immune checkpoint inhibitors in prostate cancer
od: Gabriel Surdacki, i dr.
Izdano: (2019-03-01)

Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases
od: Andreas von Knethen, i dr.
Izdano: (2021-10-01)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
od: Alberto Bongiovanni, i dr.
Izdano: (2021-05-01)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
od: Ya Xu, i dr.
Izdano: (2020-10-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
od: Edyta Zyla, i dr.
Izdano: (2021-08-01)

The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers
od: Emily Hensler, i dr.
Izdano: (2022-07-01)

Key questions about the checkpoint blockade-are microRNAs an answer?
od: Mihnea Dragomir, i dr.
Izdano: (2018-06-01)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
od: Maria Georganaki, i dr.
Izdano: (2018-12-01)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
od: William L. Redmond, i dr.
Izdano: (2023-02-01)

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
od: Reid P. Bissonnette, i dr.
Izdano: (2021-08-01)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
od: Ji Won Han, i dr.
Izdano: (2021-09-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
od: Kübra KAHVECİ, i dr.
Izdano: (2019-12-01)

Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
od: Zachary S. Buchwald, i dr.
Izdano: (2018-12-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
od: Amjad Zafar, i dr.
Izdano: (2024-11-01)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
od: Jiaxin Zhou, i dr.
Izdano: (2022-07-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
od: Adel Naimi, i dr.
Izdano: (2022-04-01)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
od: Zhanjun Guo, i dr.
Izdano: (2022-03-01)

Profiling targetable immune checkpoints in osteosarcoma
od: Troy A McEachron, i dr.
Izdano: (2018-12-01)

The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
od: Deniz Can Guven, i dr.
Izdano: (2022-10-01)

Commentary: Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model
od: Kuti Baruch, i dr.
Izdano: (2020-05-01)

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy
od: Leona Raskova Kafkova, i dr.
Izdano: (2024-02-01)

Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
od: Shuai Wang, i dr.
Izdano: (2018-08-01)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
od: Silvia Pesce, i dr.
Izdano: (2019-06-01)

In Search of Better Peptide-(Derived from PD-L2)-Based Immune Checkpoint Inhibitors
od: Boris Klebansky, i dr.
Izdano: (2024-05-01)